The Warsaw-based company has sued seven law firms this year and sent warning letters to at least three more, saying their ads and Internet postings distorted the safety record of its $1.8 billion-a-year knee business.
Rochester Medical Implants plans to move operations from Rochester to Noblesville in October. The company has 28 employees.
Indianapolis-based DGP Intelsius LLC, a manufacturer and distributor of temperature-controlled packaging, announced on Tuesday morning that it plans to add 80 jobs by 2014 as part of an $870,000 expansion.
An investment firm projects that the Elanco animal-health business will generate sales of nearly $2 billion by 2012 and surpass $3 billion by 2018.
Former Eli Lilly and Co. vice president Richard Dimarchi, BioCrossroads President David Johnson, angel investor Oscar Moralez and Purdue University Senior Vice President Alan Rebar discuss issues ranging from the depth of the life sciences industry in Indiana to venture capital and Purdue’s Discovery Park.
The U.S. Food and Drug Administration’s growing reputation for unpredictability is spurring some Indianapolis companies to join counterparts elsewhere and introduce products in Europe. The upshot is that some Americans may never benefit from innovations occurring in their backyards.
StepStone Business Partners has added a chapter in biotech hotbed Warsaw as part of what it hopes will eventually become a statewide network.
Second-quarter revenue for the Indianapolis-based company increased 18 percent, to $1.5 billion. The company attributed the gain to higher prices and stronger demand for its products.
Pfizer Inc., the world’s biggest drugmaker, said it isn’t interested in breaking up its animal health unit after Indianapolis-based Eli Lilly and Co. expressed interest in buying some of its products.
The Indianapolis Convention & Visitors Association plans to attract more life sciences conferences.
The High Court in London on Tuesday denied Lilly’s request for a judgment without trial against Neopharma Ltd., the closely held company that has European marketing rights for the generic version of the drug known chemically as olanzapine.
Eli Lilly and Co.’s foray into combination drugs is well-timed because the company could take advantage of some the world’s most successful biotech medicines, which are about to see their patents expire.
Indianapolis-based drugmaker Eli Lilly on Tuesday will announce a multimillion-dollar investment to develop drugs that act like two medicines in one. Lilly plans to add more scientists to back the effort.
The U.S. government needs to open its borders to attract and retain talented scientists for drugmakers to employ, Eli Lilly & Co. CEO John Lechleiter plans to tell a technology conference Thursday.
Officials on Thursday shared details of a long-term plan to redevelop an industrial stretch northwest of downtown with the goal of attracting hundreds of residents and dozens of high-tech companies to the area.
Despite enjoying rising revenues and profits, companies haven’t followed with big increases in job numbers.
Vi Shukla is a scientific leader at Indianapolis-based Dow AgroSciences LLC, focused on its Exzact Precision Technology tools for genetic engineering of plants and crops. Dow Agro used the technology in its own crop seed products, and has also been licensing for use in tomatos and trees.
The city of Indianapolis plans to announce a major initiative to turn a stretch of 16th Street northwest of downtown into a hub for biotechnology and other high-tech companies.
Colleen Hittle became CEO and sole owner of the Indianapolis-based pharmaceutical and medical device consulting firm in April.
Monday's Supreme Court decision is a victory for companies that collaborate with universities in research. Indianapolis-based Eli Lilly and Co. was among the companies that supported Roche.
